Montreal platelet syndrome: a defect in calcium-activated neutral proteinase (calpain)

Blood. 1989 Aug 1;74(2):715-21.

Abstract

Platelets from patients with Montreal platelet syndrome (MPS) consistently display a defect in the mechanisms that regulate platelet size during shape change and undergo spontaneous aggregation and stir-induced microaggregate formation. We now provide data that the surface glycoprotein composition of MPS platelets is indistinguishable from that of normal platelets. However, a defect in calcium-activated neutral proteinase (calpain) was detected in MPS platelets. The specific activity of calpain in the cytosolic fraction of platelets from four MPS patients was found to be only 30% of that in platelets from normal control donors (n = 18, P less than .001). Additionally, platelets from MPS patients (n = 3) contained only 50% (P less than .001) of the calpain I catalytic subunit antigen found in platelets from normal control donors (n = 9). Platelets from the asymptomatic father/grandfather of the MPS patients had normal amounts of both total calpain proteolytic activity and calpain I catalytic subunit antigen. This represents the first report of a defect in calpain in human cells. The abnormally low calpain activity in MPS platelets may account for the platelet defects characteristic of this disorder.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Blood Platelet Disorders / blood*
  • Blood Platelet Disorders / genetics
  • Blood Proteins / analysis
  • Calpain / blood
  • Calpain / deficiency*
  • Calpain / metabolism
  • Catalysis
  • Female
  • Humans
  • Hydrolysis
  • Immunoelectrophoresis, Two-Dimensional
  • Isoantigens / isolation & purification
  • Male
  • Platelet Aggregation
  • Platelet Membrane Glycoproteins / blood
  • Subcellular Fractions / immunology
  • Syndrome

Substances

  • Blood Proteins
  • Isoantigens
  • Platelet Membrane Glycoproteins
  • Calpain